OpportunityAnalyzer: Acromegaly and Gigantism – Opportunity Analysis and Forecast to 2018

Published in ; US $ 7995 Onwards; Publisher: GlobalData

GlobalData estimates the 2013 sales for acromegaly and gigantism at approximately $588m across the 6MM covered in this report. The market will grow moderately at a CAGR of 3.74% during the five year forecast period, generating sales of approximately $707m at the end of 2018. Growing at a CAGR of 4.5[...]

2014 Market Research Report on Global Disposable Syringe Industry

Published in ; US $ 2600 Onwards; Publisher: QYResearch Group

This is a professional and depth research report on Global Disposable Syringe industry For overview analysis, the report introduces Disposable Syringe basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analys[...]

2014 Market Research Report on Global Vitamin K3 Industry

Published in ; US $ 2600 Onwards; Publisher: QYResearch Group

This is a professional and depth research report on Global Vitamin K3 industry For overview analysis, the report introduces Vitamin K3 basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis, etc For i[...]

Zimbabwe Pharmaceuticals and Healthcare Report Q1 2015

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: The World Health Organization's approval of a quality control laboratory for medicines in Zimbabwe is a positive step for the country's pharmaceutical market. It will help to reduce the proportion of counterfeit medicines in circulation and increase the country's attractiveness[...]

United Kingdom Pharmaceuticals and Healthcare Report Q1 2015

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: The pharmaceutical and healthcare markets of the United Kingdom are driven by government spending in the form of the National Health System (NHS), which accounts for over 80% of total healthcare spending. With a higher prevalence of non-communicable diseases, coupled with an ag[...]

Philippines Pharmaceuticals and Healthcare Report Q1 2015

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: Our outlook for the Philippines' pharmaceutical sector remains bullish, driven by an increasing population and high burden of disease profile. Generic medicines will continue to account for an increasing share of pharmaceutical sales in the Philippines, galvanised by expanding [...]

Kazakhstan Pharmaceuticals and Healthcare Report Q1 2015

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: Plans to boost government spending on healthcare will be positive for the pharmaceutical industry as well as other participants in the healthcare sector. Over the longer term, the introduction of compulsory health insurance will create a large pool of funding for further growth[...]

India Pharmaceuticals and Healthcare Report Q1 2015

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: The new government under Prime Minister Modi bodes well for the overall pharmaceutical sector. The proposed introduction of universal healthcare in 2015 coupled with small regulatory reform will help unlock the potential of the large Indian market. Headline Expenditure Pr[...]

Finland Pharmaceuticals and Healthcare Report Q1 2015

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: Finland, like many other Western countries, has a mature pharmaceutical market where growth is slowing. Although an ageing population will drive the demand for high-value medicines for the treatment of long-term illnesses, drug manufacturers will be pressured to reduce drug pri[...]

China Pharmaceuticals and Healthcare Report Q1 2015

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: Improvements in intellectual property protection, an ageing population and increasing access to healthcare will drive the robust growth of China's pharmaceutical market. This will attract foreign drug manufacturers despite the downside risks of pharmaeconomics and the governmen[...]